LINC00602

Across TCGA pan-cancer cohorts, LINC00602 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated LINC00602 data layer.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher LINC00602 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC00602 expression acts as an unfavorable survival marker, although some lineages such as KIRC and THYM show a favorable association.

ACC, LUAD, and STAD are the cancer types where LINC00602 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.228	0.658	<.001	113	view →
LUAD	DFS	Tertile	All	0.719	0.824	<.001	90	view →
STAD	OS	Quartile	All	0.544	0.748	<.001	77	view →
THCA	OS	Quartile	All	0.985	0.997	<.001	48	view →
DLBC	OS	Tertile	III,IV	0.175	0.874	.025	27	view →
CHOL	OS	Tertile	All	0.135	0.809	.001	27	view →
LUSC	OS	Tertile	III,IV	0.182	0.794	.002	27	view →
BRCA	DFS	Tertile	II,III,IV	0.845	0.906	.007	24	view →
COAD	OS	Tertile	IV	0.039	0.660	<.001	18	view →
LIHC	DFS	Tertile	III,IV	0.091	0.358	<.001	18	view →
PRAD	DFS	Tertile	All	0.870	0.943	.007	18	view →
UCEC	OS	Tertile	All	0.813	0.887	.013	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

LINC00602–ACC (DFS)

Open the ACC breakdown →